Tolvaptan
Ended Awarded
- Contract number
- 36C25220F0257
- Awardee
-
Otsuka America Pharmaceutical Inc. UEI QKABLBMA8FT9
- Awarding agency
-
Veterans Integrated Service Network 12
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $10,102
Award facts
- Contract value 100% obligated
- $10,102.19 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Pittsburgh, PA 15275, USA
Award details come from SAM.gov/FPDS.
About this award
The U.S. Department of Veterans Affairs, Veterans Integrated Service Network 12, awarded a delivery order valued at $10,102.19 to Otsuka America Pharmaceutical Inc. on April 15, 2020, for the supply of Tolvaptan, a specialty pharmaceutical used to treat autosomal dominant polycystic kidney disease and hyponatremia. This firm fixed-price delivery order, with performance in Pittsburgh, Pennsylvania, does not utilize a set-aside designation and is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The award represents a task order against Otsuka America's larger Indefinite Delivery Vehicle—a blanket purchase agreement valued at approximately $83.3 million for Jynarque (tolvaptan) that extends through March 26, 2026, enabling VA facilities across multiple Integrated Service Networks to procure this critical pharmaceutical treatment.
Otsuka America Pharmaceutical Inc., headquartered in Rockville, Maryland, is a for-profit pharmaceutical manufacturer specializing in complex medical treatments with an established track record supplying specialty pharmaceuticals to the VA's Veterans Health Administration. The company maintains substantial federal contracting capabilities, including a $396 million Federal Supply Schedule contract for pharmaceuticals and hematology-related products, positioning it as a key supplier of specialized medications to the federal healthcare system. This delivery order supports the VA's mission to provide veterans with access to advanced pharmaceutical therapies, with performance scheduled for completion by April 27, 2020.
Quick answers
Who was awarded contract 36C25220F0257?
36C25220F0257 was awarded to Otsuka America Pharmaceutical Inc. by Veterans Integrated Service Network 12 (Veterans Health Administration) on April 15, 2020.
How much is contract 36C25220F0257 worth?
The government has obligated $10,102 on 36C25220F0257.
Is contract 36C25220F0257 an order under another contract?
Yes. 36C25220F0257 is a delivery order under 36F79720D0099, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C25220F0257 competed?
The extent of competition for 36C25220F0257 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award